05:57 EST Novo Nordisk (NVO): Cagrisema weight loss showed superiority over semaglutide
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- End to tirzepatide shortage has read on Hims GLP-1 trajectory, says Leerink
- Lennox to replace Catalent in S&P 500 at open on 12/23
- Novo Nordisk Completes Strategic Acquisition to Enhance Manufacturing Capacity
- Trump’s Key Advisors Are Split on Whether Medicare Should Cover Weight-Loss Drugs
- Viking Therapeutics lower after Merck signs pact with Hansoh for GLP-1 drug